Subscribe to RSS
DOI: 10.1055/a-2794-5001
Inherited Thrombophilia as a Risk Factor for Persistent Left Ventricular Thrombus Following Acute Myocardial Infarction
Authors
Funding Information This study was supported by the Jagiellonian University Medical College (K/ZDS/002936 to A.Undas).

Abstract
Background
Left ventricular thrombus (LVT) commonly complicates ST-segment elevation myocardial infarction (MI), and up to 30% of LVT may persist despite anticoagulation. Data linking post-MI LVT and inherited thrombophilias are sparse.
Methods
A total of 148 consecutive MI patients with LVT at a mean age of 63.9 (6.9) years were referred for further workup. After 3 months of oral anticoagulation, screening for factor V Leiden (FVL) and prothrombin G20210A variant, protein S, protein C, and antithrombin deficiency was performed. Subjects with antiphospholipid syndrome were not eligible. Thrombus persistence was assessed after 3 and 6 months of anticoagulation.
Results
Inherited thrombophilias were identified in 34 (23%) patients, including 18 (52.9%) with FVL, 9 (26.5%) with prothrombin G20210A variant, 3 (8.8%) with protein C deficiency, and 4 (11.8%) with protein S deficiency. Carriers of thrombophilias were similar to non-thrombophilic subjects, except for higher fibrinogen in the former group. Inherited thrombophilias were associated with LVT persistence after 3 and 6 months post MI (25 [73.5%] vs. 50 [43.9%], p = 0.002 and 20 [58.8%] vs. 24 [21.1%], p < 0.001, respectively). Inherited thrombophilias were independently associated with an increased risk of persistent LVT 3 and 6 months post MI (OR 2.75, 95% CI 1.13–6.74, p = 0.026 and OR 4.06, 95% CI 1.57–10.51, p = 0.004, respectively).
Conclusion
Our findings suggest that inherited thrombophilias may predispose to LVT persistence despite anticoagulation in MI survivors. Thrombophilia screening may help identify a subgroup likely to benefit from prolonged anticoagulation.
Publication History
Received: 10 July 2025
Accepted: 21 January 2026
Article published online:
09 February 2026
© 2026. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi Jr JL, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment. JAMA Cardiol 2018; 3 (07) 642-649
- 2 Lattuca B, Bouziri N, Kerneis M. et al; ACTION Study Group. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol 2020; 75 (14) 1676-1685
- 3 Levine GN, McEvoy JW, Fang JC. et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. Circulation 2022; 146 (15) e205-e223
- 4 Yang Q, Quan X, Wang C. et al. A prediction model for left ventricular thrombus persistence/recurrence: based on a prospective study and a retrospective study. Thromb J 2023; 21 (01) 50
- 5 Byrne RA, Rossello X, Coughlan JJ. et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44 (38) 3720-3826
- 6 Haller PM, Kazem N, Agewall S. et al. Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2024; 10 (05) 444-453
- 7 Stevens SM, Woller SC, Bauer KA. et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016; 41 (01) 154-164
- 8 Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015; 114 (05) 885-889
- 9 Kujovich JL, Factor V. Factor V Leiden thrombophilia. Genet Med 2011; 13 (01) 1-16
- 10 Wypasek E, Corral J, Alhenc-Gelas M. et al. Genetic characterization of antithrombin, protein C, and protein S deficiencies in Polish patients. Pol Arch Intern Med 2017; 127 (7-8): 512-523
- 11 Natorska J, Corral J, de la Morena-Barrio ME. et al. Antithrombin deficiency is associated with prothrombotic plasma fibrin clot phenotype. Thromb Haemost 2023; 123 (09) 880-891
- 12 Chiasakul T, De Jesus E, Tong J. et al. Inherited thrombophilia and the risk of arterial ischemic stroke: a systematic review and meta-analysis. J Am Heart Assoc 2019; 8 (19) e012877
- 13 Ryu J, Rämö JT, Jurgens SJ. et al. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood 2024; 143 (23) 2425-2432
- 14 Camaj A, Fuster V, Giustino G. et al. Left ventricular thrombus following acute myocardial infarction: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79 (10) 1010-1022
- 15 Anjum F, Gilani M, Latif M, Sattar A, Ashraf H, Rafaqat S. The role of coagulation in heart failure: a literature review. Curr Heart Fail Rep 2024; 21 (04) 277-291
- 16 Doud DN, Jacobs WR, Moran JF, Scanlon PJ. The natural history of left ventricular spontaneous contrast. J Am Soc Echocardiogr 1990; 3 (06) 465-470
- 17 Mróz K, Paszek E, Polak M, Undas A. Prothrombotic fibrin clot phenotype as a risk factor for persistent left ventricular thrombus following acute myocardial infarction. J Thromb Haemost 2025; 23 (09) 2903-2912
- 18 Steg PG, James SK, Atar D. et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
- 19 Roffi M, Patrono C, Collet JP. et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
- 20 Cieslik J, Mrozinska S, Broniatowska E, Undas A. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 2018; 131 (07) 797-807
- 21 Cooper PC, Pavlova A, Moore GW, Hickey KP, Marlar RA. Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH. J Thromb Haemost 2020; 18 (02) 271-277
- 22 Marlar RA, Gausman JN, Tsuda H, Rollins-Raval MA, Brinkman HJM. Recommendations for clinical laboratory testing for protein S deficiency: communication from the SSC committee plasma coagulation inhibitors of the ISTH. J Thromb Haemost 2021; 19 (01) 68-74
- 23 Van Cott EM, Orlando C, Moore GW, Cooper PC, Meijer P, Marlar R. Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH. J Thromb Haemost 2020; 18 (01) 17-22
- 24 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (03) 236-239
- 25 Valeriani E, Pannunzio A, Menichelli D. et al. Management of antithrombotic therapy in left ventricular thrombus: a position paper of the Italian Society of Hemostasis and Thrombosis (SISET). Thromb Haemost 2025; . Epub ahead of print
- 26 Jenab Y, Sadeghipour P, Mohseni-Badalabadi R. et al. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention 2025; 21 (01) 82-92
- 27 Meyer MR, Witt DM, Delate T. et al. Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thromb Res 2015; 136 (06) 1160-1164
- 28 Erbay AR, Turhan H, Senen K. et al. Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance. Coron Artery Dis 2004; 15 (02) 107-110
- 29 Dowaidar M, Settin A. Risk of myocardial infarction related to factor V Leiden mutation: a meta-analysis. Genet Test Mol Biomarkers 2010; 14 (04) 493-498
- 30 Cosmi B, Legnani C, Pengo V. et al; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thromb Haemost 2013; 109 (03) 510-516
- 31 Uçar F, Celik S, Ovali E. et al. Coexistence of prothrombic risk factors and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2004; 59 (01) 33-39
- 32 Bereczky Z, Balogh L, Bagoly Z. Inherited thrombophilia and the risk of myocardial infarction: current evidence and uncertainties. Kardiol Pol 2019; 77 (04) 419-429
- 33 Swan D, Connors JM, Thachil J. Dilemmas in hematology: consults in patients with arterial thrombosis. J Thromb Haemost 2023; 21 (03) 421-432
- 34 Yetkin E, Erbay AR, Ayaz S. et al. Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance. Coron Artery Dis 2000; 11 (03) 269-272
- 35 Mizia-Stec K, Gasior Z, Duława J, Janowska M, Pysz P, Mizia M. Churg-Strauss syndrome and congenital factor Leiden thrombophilia as nontypical causes of intracardiac thrombosis. Heart Vessels 2006; 21 (04) 263-266
- 36 Aggeli C, Pietri P, Vavouranakis M, Felekos I, Tatsis H, Stefanadis C. Sequential thromboembolic events after primary angioplasty in a patient with acute anterior myocardial infarction. Eur Heart J Acute Cardiovasc Care 2012; 1 (04) 341-343
- 37 Pahuja M, Ainapurapu B, Abidov A. Large left ventricular thrombus in a patient with systemic and venous thromboembolism secondary to protein C and S deficiency. Case Rep Cardiol 2017; 2017: 7576801
- 38 Celik S, Ovali E, Baykan M. et al. Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2001; 56 (01) 1-6
- 39 Middeldorp S, Nieuwlaat R, Baumann Kreuziger L. et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023; 7 (22) 7101-7138
- 40 Tang LV, Morange PE, Corral J. et al; International Thrombophilia Collaborative Initiative. Practical guideline for major hereditary thrombophilia. Innovation (Camb) 2025; 6 (06) 100890
- 41 van Sluis GL, Söhne M, El Kheir DY, Tanck MW, Gerdes VEA, Büller HR. Family history and inherited thrombophilia. J Thromb Haemost 2006; 4 (10) 2182-2187
- 42 Vossen CY, Conard J, Fontcuberta J. et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004; 2 (09) 1526-1532
- 43 Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 2019; 17 (04) 645-656
- 44 Kovac M, Ignjatovic V, Orlando C, Bereczky Z, Hunt BJ. The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. J Thromb Haemost 2024; 22 (11) 3322-3329
- 45 Lavigne-Lissalde G, Sanchez C, Castelli C. et al. Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost 2010; 8 (05) 942-949
- 46 Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. In: StatPearls. StatPearls Publishing; 2025. . Accessed October 21, 2025 at: http://www.ncbi.nlm.nih.gov/books/NBK519570/
- 47 Klajmon A, Chmiel J, Ząbczyk M. et al. Fibrinogen β chain and FXIII polymorphisms affect fibrin clot properties in acute pulmonary embolism. Eur J Clin Invest 2022; 52 (04) e13718
- 48 Mas-Llado C, Rossello X, González-Del-Hoyo M. et al. Secondary prevention therapies in real-world patients with myocardial infarction: eligibility based on randomized trials supporting European and American guidelines. Am J Med 2024; 137 (02) 137-146.e10
- 49 Lisowska A, Makarewicz-Wujec M, Dworakowska AM, Kozłowska-Wojciechowska M. Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL-ACS). J Clin Pharm Ther 2019; 44 (03) 471-478
- 50 Mahmoud KD, Hillege HL, Jaffe AS, Lennon RJ, Holmes Jr DR. Biochemical validation of patient-reported symptom onset time in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2015; 8 (06) 778-787